Skip to main content

Table 1 Patient demographics and characteristics

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

Parameter All patients diagnosed with stage IIIB–IV NSCLC
(2012–2016)
Patients diagnosed
with stage IIIB–IV NSCLC
in 2012–2014
(no treatment data available)
Patients diagnosed with stage IIIB–IV NSCLC in 2015–2016 (treatment data available) P valuea
All
N = 1008
All
N = 616
All
N = 392
 
Median age (IQR), years 65 (58–73) 66 (58–74) 65 (57–72)  
Age range 21–92 21–92 27–90  
Age at diagnosis in years, n (%)     0.854
  < 65 478 (47.4) 288 (46.8) 190 (48.5)
 65–74 307 (30.5) 189 (30.7) 118 (30.1)
  ≥ 75 223 (22.1) 139 (22.6) 84 (21.4)
Sex, n (%)     0.316
 Male 762 (75.6) 459 (74.5) 303 (77.3)
 Female 246 (24.4) 157 (25.5) 89 (22.7)
TNM stage, n (%)     0.290
 IIIB 154 (15.3) 100 (16.2) 54 (13.8)
 IV 854 (84.7) 516 (83.8) 338 (86.2)
Histology, n (%)     0.043
 NSQ 720 (71.4) 431 (70.0) 289 (73.7)
 Adenocarcinoma 713 (70.7) 429 (69.6) 284 (72.4)
 SQ 210 (20.8) 127 (20.6) 83 (21.2)
 NSCLC NOS 57 (5.7) 45 (7.3) 12 (3.1)
 Other histologies 21 (2.1) 13 (2.1) 8 (2.0)
  1. NA not available, NSCLC non-small cell lung cancer, SD standard deviation, IQR interquartile range, TNM tumour, node, and metastasis, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma, NOS not otherwise specified
  2. a Chi-square test